Repair. Regenerate. Restore.
At the core of OhhMed Medical’s innovation is our patented Tissue Restorative RF Technology – a non‑invasive platform that targets the structural, vascular and functional causes of male urological conditions.
Unlike drugs or injections that provide temporary symptom relief, Vertica® activates the body’s natural repair mechanisms to support longer‑term tissue recovery.
Vertica® is the only device designed to improve venous leakage – a key cause of erectile dysfunction for which there is no established non‑surgical solution.
By promoting collagen regeneration, improving local blood flow and supporting the biomechanical integrity of penile tissue, Vertica® offers a new therapeutic approach without ongoing medication or invasive procedures.
Collagen
remodelling
improves tunica albuginea elasticity and strength
Microvascular
regeneration
restores arterial inflow and endothelial function
Pelvic floor
support
enhances erectile rigidity and recovery post-surgery
Venous
sealing
reduces venous leak by tightening tunica and cavernosal tissue
How it works
Our RF energy is delivered at precise, therapeutic depths to the penile shaft or pelvic floor via a dedicated applicator.
Controlled thermal effects stimulate biological repair mechanisms without damaging surrounding structures.
Each session is designed to gradually rebuild functionality over time – providing cumulative, measurable results with no downtime, no discomfort and no systemic side effects.
Designed for Versatility
The Vertica platform is engineered to serve both home users and medical professionals.
Our home-use device provides a discreet, non-invasive solution for individuals seeking to manage erectile dysfunction independently. For clinical applications, Vertica® Pro offers a sophisticated, professional-grade system designed to deliver targeted, comprehensive treatments with advanced therapeutic features beyond those of the home-use device.
Each version uses the same core RF technology, adapted to suit different stages of care – from early intervention to structured recovery.
Professional Platform
Vertica Pro
Professional in-clinic platform for urologists and men’s health clinics.
Includes both penile and pelvic applicators, real-time energy control and patient progress tracking.
Home-Use
Vertica Plus
A discreet device for self-administered treatment at home, with smartphone app integration for tracking usage, reminders and monitoring IIEF scores to support ongoing treatment.
Vertica Plus empowers patients to take control of their recovery within a guided framework, ensuring effective programme adherence and personalised care.
Home-Use
Vertica
A simple-to-use handheld device designed for independent treatment at home enabling patients to manage their condition comfortably and confidently.
Recommended for 30-minute sessions, conducted twice or three times weekly, to fit easily into daily routines.
Clinical Evidence
Israel Pilot Study
A pioneering trial led by Prof. Ilan Gruenwald at Rambam Healthcare Campus (Haifa) involved 28 men with mild-to-moderate organic erectile dysfunction. Participants self-administered 12 Vertica® treatments over 8 weeks. Results showed:
- 89% (25 of 28) achieved significant improvements in IIEF‑EF scores (≥2–5 point increases depending on baseline severity), with an average increase of +7.6 points.
- Meaningful gains in erection hardness, treatment satisfaction (average EDITS score 76.8), and sexual quality of life (SQOL score ~67.6).
- No adverse events reported; strong tolerability and ease of use were noted.
Read more in the International Journal of Impotence Research (publication date: November 2024) and view the Rambam center report.
U.S. Pivotal Trial (ClinicalTrials.gov)
A randomised, double-blind, sham-controlled study is underway across six U.S. centers – including UCI Health and Cleveland Clinic – to evaluate the Vertica RF device’s safety, efficacy, tolerability, and patient satisfaction:
- Enrollment: ~98 men with mild-to-moderate ED
- Intervention: In-clinic orientation followed by 6 months of at-home treatment
- Primary outcome: Change in IIEF‑EF domain score at 12 weeks
- Secondary outcomes: Objective erection hardness, quality-of-life, satisfaction, and safety
- Current status: Recruiting (started Nov 29, 2023; completion expected Oct 28, 2025).
You can explore full protocol details at the NIH’s ClinicalTrials.gov listing: [“Safety and Efficacy of the VERTICA® RF Device for the Treatment of ED” (NCT06167733)]
A Platform for the Future of Men’s Health
Our goal is to lead the shift toward restorative male urology – where regeneration replaces replacement, and lasting function takes precedence over short-term fixes.
With scalable device formats, growing clinical data, and unmatched patient outcomes, the Vertica RF platform is built not only for today’s problems – but tomorrow’s standards of care.
